CO-RADIA
Three aerospace leaders – Aernnova, Leonardo and AFuzion – will partner with Radia on WindRunner™, the world’s largest aircraft. Radia is developing WindRunner to deliver the largest, most efficient wind turbine blades, expand the reach of wind energy and transform its economics, enabling the world to meet its climate goals.
The companies are joining Radia’s innovation ecosystem. They will be available to discuss the partnerships at the 2024 Farnborough International Airshow.
Aernnova will partner with Radia on the development of the aircraft’s wing and engine pylons. Leonardo will develop the fuselage. AFuzion will provide safety and certification consulting.
The partnership agreements are the latest step forward for WindRunner, an aircraft designed for its primary mission: To fly large turbine blades – up to 105m in length, longer than a football pitch – directly to wind farm sites, landing on semi-prepared dirt runways as short as 1,800m (6,000 ft). It will overcome logistical barriers that today prevent the expansion of onshore wind energy. Wind turbines become more effective and efficient the larger they are. But long turbine blades are extremely difficult and expensive to move by ground transport because literal roadblocks – bridges, tunnels and road curves – get in the way.
WindRunner will fly over these roadblocks, enabling the deployment of the largest, most efficient onshore wind turbines today and the even larger ones of the future – what Radia calls GigaWind™.
The result will be widespread availability of consistent, lowest-cost clean energy in more locations and at industrial scale for the grid, green fuel production including sustainable aviation fuel (SAF), and commercial power users such as data centers and hyperscalers. The market for onshore wind energy is estimated at up to $10 trillion by 2050 – as many as 1 million wind turbines.
Partners Will Help Radia Fulfill Its Mission and Can Seize a New Opportunity for Aerospace
“WindRunner is an opportunity for the aerospace industry to have a decisive impact on climate change, diversify into the energy industry and seize an enormous market opportunity,” said Mark Lundstrom, Radia’s CEO. “We are extremely pleased and excited that Aernnova, Leonardo and AFuzion – three companies at the forefront of aerospace design, development, and engineering – have chosen to partner with us on this critically important project.”
Partners Attracted by Scope and Ambition of Project, Importance of its Goals, Say Aernnova, Leonardo and AFuzion Executives
“We are excited and proud to participate in the world’s largest aircraft, especially in view of its mission,” said Ricardo Chocarro, CEO of Aernnova. “Based on my previous experience in this sector of the wind turbine industry, I can affirm the importance of the solution that WindRunner provides. The agreement with Radia for the development of the WindRunner project positions us in the wing and engine pylon design and manufacturing support, recognizing our expertise for the design and development of this ambitious project.”
Stefano Bortoli, Leonardo Aerostructures Division MD, said: “The WindRunner initiative is an interesting example of how the aerospace industry continues to provide a key contribution to sustainability, with a range of diversified solutions to the benefit of multiple sectors. Also, Leonardo has a deep experience in the energy sector with its technologies in aviation, including wind farms. Therefore, it gives us great pleasure to support this initiative with our established aerostructure engineering know-how and capabilities.”
“WindRunner must operate safely in a wide range of operating environments,” said AFuzion CEO Vance Hilderman. “And the urgency of the climate crisis demands that it move systematically through the certification process so that it can enter into service. AFuzion is eager to bring our capabilities to bear to support WindRunner’s progress from design all the way through to deployment.”
Aerospace Can Help Make Renewables Viable and Climate Goals Achievable
“WindRunner is exciting and consequential,” said Lundstrom, “not only because of the scope of the project but also because of its critical importance to the viability and the economics of renewable energy and society’s ability to meet our growing need for power while achieving our climate goals. Our partnership with Aernnova, Leonardo and AFuzion will enable us to deliver on that promise, fulfill our mission, and achieve a significant impact on renewables.”
About Radia
Radia is an energy company building a unique aerial transportation solution, the WindRunner, to radically expand the scope and scale of the onshore wind energy industry. Simultaneously, Radia is developing a world-class portfolio of wind energy projects to leverage this solution and partnering with the world’s largest energy and industrial companies to support their energy transition plans. This unique combination of capabilities allows Radia to bring together the ecosystem of stakeholders and partners to enable GigaWind – the largest onshore wind turbines manufactured by our partners deployed to more places to deliver differentiated low-cost clean electricity and, correspondingly, green molecules and synthetic fuels. Radia has been selected both as a World Economic Forum Global Unicorn and as an Endeavor Entrepreneur in their competitive International Selection Panel process. For more information: www.radia.com.
About Aernnova
Aernnova is a leading company specialized in the design, manufacturing, maintenance, and services of aerostructures and their components such as wings, empennages, fuselages, stabilizers, bulkheads, doors and moving surfaces for the world's leading aircraft manufacturers. Aernnova is a company committed to sustainability, technological development and digitization. Headquartered in Spain, Aernnova is among the world's leading Tier 1 aerostructures suppliers with a global presence through its manufacturing and engineering facilities in Spain, U.K., U.S.A., Portugal, Mexico and Brazil. More information about Aernnova can be found in: www.aernnova.com
About Leonardo
Leonardo is an international industrial group, among the main global companies in Aerospace, Defence, and Security (AD&S). With 53,000 employees worldwide, the company approaches global security through the Helicopters, Electronics, Aircraft, Cyber & Security and Space sectors, and is a partner on the most important international programmes, within these sectors, such as Eurofighter, NH-90, FREMM, GCAP, and Eurodrone. Leonardo has significant production capabilities in Italy, the UK, Poland, and the USA. Leonardo utilises its subsidiaries, joint ventures, and shareholdings, which include Leonardo DRS (72.3%), MBDA (25%), ATR (50 %), Hensoldt (22.8%), Telespazio (67%), Thales Alenia Space (33%), and Avio (29.6%). Listed on the Milan Stock Exchange (LDO), in 2023 Leonardo recorded new orders for €17.9 billion, with an order book of €39.5 billion and consolidated revenues of €15.3 billion. Included in the MIB ESG index, the company has also been part of the Dow Jones Sustainability Indices (DJSI) since 2010. More information about Leonardo can be found in: www.leonardo.com
About AFuzion
AFuzion specializes in avionics certification training and consulting, providing comprehensive solutions to help companies navigate complex regulatory requirements. With a focus on DO-254, AC 20-152A, and A(M)C 20-152A compliance, AFuzion's expert team offers invaluable guidance and training to ensure the development of reliable and safe avionics hardware.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718714101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
